A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...
Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
The FDA is raising the bar for approval of CAR T-cell therapies in oncology. | The FDA is raising the bar for approval of CAR ...
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T ...
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...
T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory ...
Cancer Research UK's Centre for Drug Development is sponsoring and conducting the phase I/II clinical trial of ALETA-001, the lead agent in Aleta Biotherapeutics' portfolio. Additional clinical trial ...
Key factors driving this growth include the rising prevalence of cancer, continuous advancements in CAR T-cell technologies, a ...
The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback